e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice
Gabrielle Fröberg, Lena Jansson, Judith Bruchfeld
Source:
Eur Respir J, 53 (2) 1801128; 10.1183/13993003.01128-2018
Journal Issue:
February
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Gabrielle Fröberg, Lena Jansson, Judith Bruchfeld. Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice. Eur Respir J, 53 (2) 1801128; 10.1183/13993003.01128-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population
Source: Eur Respir J 2005; 26: Suppl. 49, 624s
Year: 2005
Clinical characteristics and treatment outcomes of patients with pulmonary tuberculosis with delayed conversion over 4 months
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Outcomes of treatment of latent tuberculosis infection in children with two different regimens
Source: Eur Respir J 2006; 28: Suppl. 50, 487s
Year: 2006
Systematic review of shorter 2-3 months regimens for treatment of latent tuberculosis
Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis
Year: 2013
Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children
Source: Eur Respir J 2004; 24: Suppl. 48, 648s
Year: 2004
Benefit of treatment of latent tuberculosis infection in individual patients
Source: Eur Respir J 2016; 47:1592-1594
Year: 2016
Benefit of treatment of latent tuberculosis infection in individual patients
Source: Eur Respir J 2015; 46: 1397-1406
Year: 2015
Benefit of treatment of latent tuberculosis infection in individual patients
Source: Eur Respir J 2016; 47:1594-1595
Year: 2016
Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy
Source: Eur Respir J 2001; 18: Suppl. 33, 314s
Year: 2001
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly
Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018
Year: 2019
Impact of smoking on outcome of treatment of tuberculosis in patients taking intermittent treatment of tuberculosis under India‘s revised tuberculosis control program
Source: Annual Congress 2008 - Health effects of passive smoking and of a smoking ban
Year: 2008
A choice of regimen improves completion for patients with latent TB infection
Source: Breathe 2008; 4: 366
Year: 2008
Clinical indicators of treatment response to Mepolizumab at 12 weeks
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients
Source: Eur Respir J 2001; 18: Suppl. 33, 340s
Year: 2001
Bedaquiline-containing regimens for chronic XDR-TB patients: up to 120 weeks after initiation
Source: International Congress 2017 – MDRTB: detection and management
Year: 2017
A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment
Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches
Year: 2014
The characteristics of previous tuberculosis treatment programmes in patients with tuberculosis relapses
Source: Eur Respir J 2001; 18: Suppl. 33, 473s
Year: 2001
When do we extend the treatment of tuberculosis (TB) more than 6 months?
Source: Annual Congress 2007 - Clinical tuberculosis
Year: 2007
Evaluation of new smear positive tuberculosis patients 5 years after initiation of treatment under a DOTS programme
Source: Annual Congress 2010 - Tuberculosis epidemiology
Year: 2010
Prevalence, screening and treatment of latent tuberculosis among oral corticosteroid recipients
Source: Eur Respir J 2014; 44: 1373-1375
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept